An FDA Panel Just Voted in Favor of Six Popular Peptides

Something happened in late July that a lot of people in the peptide world were waiting on. On July 23 and 24, 2026, an FDA advisory committee voted on seven peptides. The short version is that the panel came out mostly in favor.

What they voted on

Seven peptides were up for review: BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon, and DSIP.

How the vote went

The panel voted to recommend six of them for the 503A compounding list. Those were BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon. DSIP was the exception.

The votes were close. On BPC-157, for example, it was eight yes, six no, and one abstention. TB-500 was about the same.

The part that surprised people

The FDA’s own scientists had recommended against adding these peptides. The panel went the other way. That does not happen every day, and it is why this made the news.

What it actually changes, which is not much yet

This is the part to be clear about.

The vote is advisory. It is not binding. The FDA does not have to follow it. Nothing about the legal status changed the day of the vote. Adding a substance to the list still takes more steps, including formal rulemaking, and the FDA has not given a date.

So if you see a headline saying these peptides are “now legal,” that is getting ahead of the facts.

Why it still matters

It is a real signal. An FDA panel looked at the evidence and voted yes, over the agency’s own objection. That tells you the conversation is shifting.

We will update the affected compound pages as the FDA takes its next steps. For now, the honest read is simple. This was a step forward, not a finish line.